UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.29M | n/a | $1.05B | 0.2% | n/c | 1 | SEC ↗ ×9 |
| 2 | Renaissance Technologies ✦ | 2.17M | n/a | $692.75M | 1.2% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.05M | n/a | $333.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | AQR Capital Management ✦ | 719.51K | n/a | $229.20M | 0.4% | n/c | 1 | SEC ↗ ×3 |
| 5 | Arrowstreet Capital ✦ | 438.68K | n/a | $139.74M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 234.92K | n/a | $74.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 103.03K | n/a | $32.82M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Gotham Asset Management ✦ | 47.59K | n/a | $15.16M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 42.02K | n/a | $13.39M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Norges Bank ✦ (passive) | 38.93K | n/a | $12.40M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 20.11K | n/a | $6.40M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Bridgewater Associates ✦ | 12.75K | n/a | $4.06M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 5.16K | n/a | $1.64M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 1.90K | n/a | $605,245 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 844 holders, 41.22M shares, $23.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 200 sh · $110,143
Officer, Director · 2.17K sh · $1.19M
Officer, Director · 281 sh · $151,874
Officer · 268 sh · $145,160
Officer, Director · 456 sh · $247,462
Officer, Director · 601 sh · $328,713
Officer, Director · 371 sh · $201,599
Officer · 1.98K sh · $1.08M
Officer · 791 sh · $430,975
Officer, Director · 825 sh · $450,347
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology